Jan 10, 2024 08:03AM
Jan 10, 2024 08:00AM
Nov 10, 2023 07:31AM
Nov 10, 2023 07:30AM
Nov 2, 2023 07:31AM
Nov 2, 2023 07:30AM
Oct 8, 2023 08:31PM Bristol Myers Squibb (BMY) to acquire Mirati Therapeutics (MRTX) for $58/share plus CVR
Oct 8, 2023 05:16PM
Oct 5, 2023 03:40PM
Sep 10, 2023 05:16AM
Sep 9, 2023 10:35PM
Aug 8, 2023 04:01PM
Jul 21, 2023 07:58AM
Jul 21, 2023 07:56AM Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation
Jun 20, 2023 08:00AM
May 8, 2023 08:30AM
Apr 26, 2023 04:36PM
Apr 26, 2023 04:34PM
Feb 28, 2023 04:01PM
Jan 19, 2023 05:00PM
Jan 19, 2023 05:00PM Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133
Dec 22, 2022 08:39AM
Dec 21, 2022 05:24PM
Dec 21, 2022 05:01PM
Dec 21, 2022 05:00PM
Dec 13, 2022 06:29AM
Dec 13, 2022 05:00AM
Dec 12, 2022 06:42PM Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Nov 8, 2022 04:10PM
Oct 12, 2022 08:00AM
Aug 3, 2022 04:01PM
Jun 3, 2022 05:24PM
May 26, 2022 05:01PM
May 26, 2022 05:00PM
May 19, 2022 04:30PM Mirati Therapeutics (MRTX) Submits MAA to EMA for Investigational Adagrasib as Treatment for Previously-Treated KRASG12C-mutated Non-Small Cell Lung Cancer
May 19, 2022 04:30PM
Apr 27, 2022 04:30PM
Mar 1, 2022 03:54PM
Mar 1, 2022 06:39AM
Feb 28, 2022 04:01PM
Feb 17, 2022 04:25PM
Feb 16, 2022 03:10AM Stifel Reiterates Mirati (MRTX) at Buy, adagrasib Approval is Likely, But Shares May be Weak as Drug Was Not Accepted For Priority Review
Feb 16, 2022 03:06AM
Feb 15, 2022 04:15PM
Feb 15, 2022 04:15PM
Nov 22, 2021 07:33AM
Nov 22, 2021 07:30AM
Nov 22, 2021 07:30AM
Nov 17, 2021 07:32AM Mirati Therapeutics (MRTX) Announces Submission of IND to FDA of MRTX1719 to Treat MTAP-Deleted Cancers
Nov 17, 2021 07:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All